We receives advance assurance for EIS status in the United Kingdom
16408
post-template-default,single,single-post,postid-16408,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies announces the publication of its paper “Biological Control of the House Dust Mite, With Potential For Use in the Prevention of Asthma” in the International Journal of Advances in Science Engineering and Technology

Evolution Biotechnologies announces the publication of its paper “Biological Control of the House Dust Mite, With Potential For Use in the Prevention of Asthma” in the International Journal of Advances in Science Engineering and Technology

Bedford, UK, May 17th 2021

Evolution Biotechnologies (www.evolutionbiotech.com), the UK based company pioneering the use of biological control to benefit human health, today announced the publication of its paper “Biological Control of the House Dust Mite, With Potential For Use in the Prevention of Asthma” in the International Journal of Advances in Science Engineering and Technology, volume 8, issue 3.

The paper is now available online at http://www.iraj.in/journal/journal_file/journal_pdf/6-661- 162020261360-64.pdf

Dr. David Harper, Evolution’s CEO, said “the publication of our initial findings in this field marks an important step for the company, and our focus is now on progressing the work towards a commercial product to help asthma and allergy sufferers around the world.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of environmentally friendly biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self- amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature and is environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;
Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.